Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a devastating necrotizing skin disease. Key to its pathogenesis is mycolactone, the exotoxin virulence factor that is both immunosuppressive and cytotoxic. The discovery that the essential Sec61 translocon is the major cellular target of mycolactone explains much of the disease pathology, including the immune blockade. Sec61 inhibition leads to a loss in production of nearly all cytokines from monocytes, macrophages, dendritic cells and T cells, as well as antigen presentation pathway proteins and costimulatory molecules. However, there has long been evidence that the immune system is not completely incapable of responding to M. ulcerans infection. In particular, IL-1beta was recently shown to be present in BU lesions, and to be induced from M. ulcerans-exposed macrophages in a mycolactone-dependent manner. This has important implications for our understanding of BU, showing that mycolactone can act as the “second signal” for
Tapering of disease-modifying antirheumatic drugs: an overview for daily practice thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint.
- Simon Sturge a un parcours riche et accompli de 40 ans dans le secteur de la biotechnologie et de l industrie pharmaceutique, le plus récemment en tant que.
MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors adnkronos.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adnkronos.com Daily Mail and Mail on Sunday newspapers.